You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

List of Excipients in API tofacitinib


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing tofacitinib

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc XELJANZ tofacitinib 0069-1001 CELLULOSE, MICROCRYSTALLINE
Pfizer Laboratories Div Pfizer Inc XELJANZ tofacitinib 0069-1001 CROSCARMELLOSE SODIUM
Pfizer Laboratories Div Pfizer Inc XELJANZ tofacitinib 0069-1001 HYPROMELLOSE 2910
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Get Started Free

Detailed excipient profiles for tofacitinib

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: CROSCARMELLOSE SODIUM

Excipient focus: D&C RED NO. 27 ALUMINUM LAKE

Excipient focus: ETHYLCELLULOSE

Excipient focus: FD&C BLUE NO. 2--ALUMINUM LAKE

Excipient focus: FERRIC OXIDE RED

Excipient focus: FERROSOFERRIC OXIDE

Excipient focus: HYPROMELLOSE 2208

Excipient focus: HYPROMELLOSE 2910

Excipient focus: LACTOSE MONOHYDRATE

Excipient focus: MAGNESIUM STEARATE

Excipient focus: POLYETHYLENE GLYCOL 3350

Excipient focus: POLYETHYLENE GLYCOL 4000

Excipient focus: PROPYLENE GLYCOL

Excipient focus: SHELLAC

Excipient focus: SODIUM LAURYL SULFATE

Excipient focus: TITANIUM DIOXIDE

Excipient focus: TRIACETIN

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links